Amicus Therapeutics (FOLD) 11.97 $FOLD Genzyme starts

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amicus Therapeutics (FOLD) 11.97 $FOLD

Genzyme starts mid-stage trial of oral Fabry disease therapy
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 10:34AM CDT

SHPG: 253.58 (+3.70), PLX: 2.08 (+0.02), SNY: 51.59 (+0.03), FOLD: 11.97 (-0.35)

Amicus Therapeutics Has Returned 37.5% Since SmarTrend Recommendation (FOLD)
Comtex SmarTrend(R) - Tue Apr 21, 9:50AM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 23rd, 2015 at $8.78. In approximately 2 months, Amicus Therapeutics has returned 37.47% as of today's recent price of $12.07.
FOLD: 11.97 (-0.35)

Technical Coverage on Biotech Stocks -- Agenus, Raptor Pharma, KaloBios Pharma, Amicus Therapeutics, and Sarepta Therapeutics
PR Newswire - Fri Apr 17, 7:45AM CDT
Editor Note: For more information about this release, please scroll to bottom.
AGEN: 6.08 (+0.21), KBIO: 0.57 (-0.02), RPTP: 10.56 (-0.17), SRPT: 13.52 (+0.04), FOLD: 11.97 (-0.35)

Uptrend Call Working As Amicus Therapeutics Stock Rises 36.3% (FOLD)
Comtex SmarTrend(R) - Tue Apr 14, 9:18AM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 23rd, 2015 at $8.78. In approximately 2 months, Amicus Therapeutics has returned 36.33% as of today's recent price of $11.97.
FOLD: 11.97 (-0.35)

Amicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day
GlobeNewswire - Thu Apr 09, 6:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, will support several activities surrounding Fabry Disease Awareness Month and International Pompe Day. The Fabry community has designated the month of April to honor and recognize those who are affected by the disease and to promote greater awareness of the disease. The goal of the Second International Pompe Day on April 15 is to foster international awareness of Pompe disease.
FOLD: 11.97 (-0.35)

Global Gaucher Disease Market 2015-2019: Key Players Include Actelion Pharmaceuticals, Genzyme, Pfizer & Shire
M2 - Wed Apr 08, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qfkgft/global_gaucher) has announced the addition of the "Global Gaucher Disease Market 2015-2019" report to their offering. The Global Gaucher Disease market to grow at a CAGR of 7.6% over the period 2014-2019 Gaucher disease is a rare, inherited metabolic disorder caused by the deficiency of the enzyme glucocerebrosidase. This in turn causes the accumulation of certain detrimental lipids in the body, especially the glycolipid glucocerebroside. The lipids are accumulated mainly within the macrophages, blood cells, spleen, liver, and bone marrow. Approximately 34 genetic mutations have been identified that leads to Gaucher disease, out of which there are four most prominent mutations that lead to more than half of the Gaucher disease globally. Some people may have no symptoms of this disease, while some experience severe complications. Some of the clinical manifestations of this disease are hepatosplenomegaly, anemia, thrombocytopenia, and skeletal abnormalities. One key trend upcoming in this market is an increase in awareness among regulatory authorities. Regulatory assistance enables drug makers in developing various treatments. The regulatory bodies are also working toward developing guidelines and providing assistance to drug manufacturers to promote research in this area. According to the report, the special provisions offered to drugs for orphan diseases such as Zavesca and Cerezyme is the major contributor to the market. Special incentives in the form of funding, guidance, and market exclusivity offer an attractive opportunity to the vendors for conducting research in this area. Further, the report states that one of the main challenges that the market faces is the limited patient population. Limited availability of treatment groups prolong the time period during which the vendor can recover R&D expenses of the drug. The restricted patient population also hinders effective evaluation of drugs based on clinical trials. To calculate the market size, the report considers revenue from the sales of various drugs used in the therapy of Gaucher disease, which includes: - Enzyme replacement therapy - Substrate reduction therapy Based on the type of molecule used for the treatment of Gaucher disease, the market is categorized into two segments: - Biologics - Small Molecules Based on the route of administration adopted for the treatment of Gaucher disease, the market is categorized into two segments: - Oral - Parenteral Based on the dosage forms of the drugs used to treat the disease, the Global Gaucher Disease market is categorized into two segments: - Solid - Liquid Key Vendors - Actelion Pharmaceuticals - Genzyme - Pfizer - Shire Other Prominent Vendors - Amicus Therapeutics - Belrose Pharma - Bionaturis - Biosidus - ISU Abxis - JCR Pharmaceuticals - LIXTE Biotechnology - Neuraltus Pharmaceuticals - Protalix BioTherapeutics - Teva Pharmaceuticals - UCB - Utrecht Holdings - Zywie For more information visit http://www.researchandmarkets.com/research/qf...al_gaucher
FOLD: 11.97 (-0.35)

25.7% Return Seen to Date on SmarTrend Amicus Therapeutics Call (FOLD)
Comtex SmarTrend(R) - Mon Apr 06, 5:05PM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 23rd, 2015 at $8.78. In approximately 1 month, Amicus Therapeutics has returned 25.74% as of today's recent price of $11.04.
FOLD: 11.97 (-0.35)

MEI Pharma Is Undervalued By At Least Half And Will Recover, Here Is Why
StockMatusow - at Seeking Alpha - Wed Apr 01, 7:30AM CDT
Written by Scott Matusow Sometimes in biotech, things do not go as expected. In the case of MEI Pharma ( MEIP ) , this was definitely one of those times when the company's cancer drug failed to meet the main goal in a mid-stage study. In...
ACAD: 38.55 (-0.20), FOLD: 11.97 (-0.35), MEIP: 2.08 (-0.16)

Uptrend Call Working As Amicus Therapeutics Stock Rises 25.4% (FOLD)
Comtex SmarTrend(R) - Fri Mar 27, 10:02AM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on February 23rd, 2015 at $8.78. In approximately 1 month, Amicus Therapeutics has returned 25.39% as of today's recent price of $11.01.
FOLD: 11.97 (-0.35)

In Case You Missed It, This Tiny Biotech Is Poised for Explosive Growth
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 24, 6:06AM CDT
Source: Amicus Therapeutics With few competitors vying for market share and typically high drug prices, rare diseases have become increasingly attractive to drug developers like Amicus Therapeutics , an emerging biotech company that is developing...
SHPG: 253.58 (+3.70), SNY: 51.59 (+0.03), FOLD: 11.97 (-0.35)

Amicus Therapeutics Slumps: FOLD Falls 6.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 23, 7:50AM CDT
Amicus Therapeutics saw a big move last session, as the company’s shares fell by nearly 7%. This reverses the recent trend for FOLD as the stock is now up around 34%
ACOR: 33.34 (-1.33), FOLD: 11.97 (-0.35)

Amicus to Seek for Migalastat's Approval in the U.S., EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 4:25PM CDT
Amicus Therapeutics, Inc. (FOLD) announced that it recently met with regulatory authorities in Europe and the U.S. in order to discuss the approval pathways for pipeline candidate - oral small molecule pharmacological chaperone migalastat HCl.
ANIP: 69.79 (+1.24), HZNP: 30.96 (+0.10), SNY: 51.59 (+0.03), FOLD: 11.97 (-0.35)

Seeking Alpha's Biotech Weekly: Biogen's Plaque Attack, Amgen Or Gilead?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
TRVN: 6.91 (-0.53), MDT: 78.01 (+0.93), CLDX: 28.95 (+1.08), FOMX: 10.94 (-0.02), AMGN: 169.10 (+0.64), AET: 107.95 (-0.41), NKTR: 10.90 (+0.16), CELG: 115.54 (+0.72), HUM: 180.01 (-0.12), CANF: 2.12 (+0.17), ANTM: 152.84 (-0.04), NVO: 56.37 (-0.17), GILD: 104.18 (-1.02), GERN: 4.20 (-0.04), AZN: 73.35 (+0.65), CLLS: 31.30 (-0.91), WCG: 82.65 (-0.33), FOLD: 11.97 (-0.35), REGN: 472.63 (+9.41), CUR: 1.96 (-0.04)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 11:45AM CDT

RALY: 15.39 (-0.17), GMAN: 8.63 (-0.17), VTAE: 14.04 (+0.02), YOKU: 16.42 (-0.21), NVGN: 7.40 (-0.30), ONTX: 2.48 (-0.05), ISNS: 2.74 (+0.01), EAC: 4.36 (-0.17), ONE: 2.73 (+0.08), VTL: 28.21 (+0.59), VGGL: 2.77 (+0.27), CALA: 12.93 (-1.06), ENVI: 1.80 (unch), CTRP: 66.14 (+0.98), VBLT: 4.37 (-0.08), PRTA: 36.96 (+0.36), NXTD: 2.60 (-0.02), OGEN: 0.97 (+0.09), FOLD: 11.97 (-0.35), BGI: 1.32 (unch)

Critical Alerts For Twitter, Ctrip.com, Prothena, Amicus Therapeutics and Ryder Released By InvestorsObserver
PR Newswire - Fri Mar 20, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TWTR, CTRP, PRTA, FOLD and R.
R: 97.95 (+1.15), CTRP: 66.14 (+0.98), PRTA: 36.96 (+0.36), TWTR: 51.73 (+0.41), FOLD: 11.97 (-0.35)

Amicus spikes on filing plans
at Investor's Business Daily - Thu Mar 19, 6:09PM CDT
Shares of the small biotech company soared 33.3% to 12.46 after it said that it would file for accelerated approval of lead drug candidate migalastat, an oral treatment for Fabry disease, following positive meetings with FDA and EU regulators. Amicus...
FOLD: 11.97 (-0.35)

Amicus Therapeutics Set to Possibly Pullback After Yesterday's Rally of 33.26%
Comtex SmarTrend(R) - Thu Mar 19, 3:56PM CDT
Amicus Therapeutics (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $11.63 to a high of $13.20. Yesterday, the shares gained 33.3%, which took the trading range above the 3-day high of $9.95 on volume of 21.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
FOLD: 11.97 (-0.35)

Freeport-McMoRan and Guess are big market movers
AP - Thu Mar 19, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
VTSS: 5.27 (-0.01), RTRX: 24.45 (+0.09), MSCC: 35.98 (-0.16), KTWO: 22.96 (-0.47), FOLD: 11.97 (-0.35), NKTR: 10.90 (+0.16), ADBE: 75.50 (+0.88)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 160

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Linq's $90M Bet on the Infrastructure Behind AI Agents

Updated Category News Views 193

Ninety million dollars just landed on the least glamorous part of the AI-agent rush: the pipes. Linq, the San Francisco private company, announced the round on November 18, 2026, led by Andreessen Horowitz, with returning backing from TQ Ventures, Mucker Capital and Abstract, plus new money from Anthos and Left Lane Capital. Ben Horowitz is joining the board. That is a...

Continue Reading
Mudrick Urges Doncasters to Test a Strategic Sale Now

Updated Category News Views 0

Castings are rarely glamorous until nobody can get them, and Mudrick Capital is betting that ugly little industrial reality could make Doncasters worth far more in a takeover than the market currently credits. The event-driven investor, which says it owns roughly 4.3% of DPC Holdings Limited, has asked the board to quietly evaluate strategic alternatives, including a sale...

Continue Reading
1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 125

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
Insta360 Tests Holiday Demand With $170 Gear Discounts

Updated Category News Views 102

A discount banner can reveal plenty about a hardware brand's priorities, and Insta360's latest Black Friday push is plainly built to put more of its ecosystem into customers' hands. The company is advertising savings of up to US$170 across cameras, gimbals, microphones, webcams, and accessories, with the promotion available for a limited time through its own store and...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 67

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 48

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 55

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 131

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading
Roof Leaks Demand Diagnosis Before the Repair Bill

Updated Category News Views 95

A brown ring on a ceiling is often the last witness, not the crime scene. That is the useful, unglamorous point in Jonathan Floyd's HelloNation discussion of roof leaks: water has plenty of ways to move after it slips past a roof's defenses. Homeowners understandably stare at the stain and assume the answer sits directly overhead. Sometimes it does. Plenty of times, it...

Continue Reading

Top 5 Most Recently Viewed Articles

BioMarin's Strong 2024 Performance Fuels 2025 Expectations

Updated Category News Views 392

BioMarin's Empowering Growth Journey Into 2025 BioMarin Pharmaceutical Inc. has marked a significant achievement with its record performance in 2024, setting a strong foundation for the upcoming year. The company demonstrated robust operational execution and is gearing up for a year of potential double-digit revenue growth as it advances its corporate strategy focusing on...

Continue Reading
Berkshire Hills Bancorp Declares Cash Dividend for Shareholders

Updated Category News Views 104

Berkshire Hills Bancorp Announces Quarterly Dividend Berkshire Hills Bancorp, Inc. (NYSE: BHLB) has recently declared a quarterly cash dividend of $0.18 per common share for its shareholders. This decision by the Board of Directors aims to reward shareholders who are on record by a specified date. Details of the Dividend Announcement The approved cash dividend will be...

Continue Reading
Maiden United Transforms Adele's Skyfall into Heavy Metal Epic

Updated Category News Views 167

Maiden United Transforms Iconic Adele Song into Heavy Metal What if Iron Maiden had recorded the legendary James Bond theme song? Maiden United, a notable tribute band dedicated to Iron Maiden, has taken that intriguing concept and turned it into reality. The band has just unveiled their latest EP entitled Agent 666, which features an electrifying heavy metal cover of...

Continue Reading
Cherokee Federal Boosts Growth with MSI, LLC Investment

Updated Category News Views 213

Cherokee Federal Expands Presence Through Strategic Investment Cherokee Federal, a division of Cherokee Nation Businesses (CNB), has recently announced a significant move in the federal contracting realm. They have acquired a majority stake in Management Science and Innovation, LLC, also known as MSI. This strategic investment marks another milestone under their...

Continue Reading
Metallurgical Coal Market Expected Growth Amid Steel Demand Spike

Updated Category News Views 125

Growth of the Metallurgical Coal Market The global metallurgical coal market is poised for significant growth, estimated at USD 95.27 billion from 2024 to 2028. This growth is largely driven by the increasing demand for steel, which is essential for numerous infrastructure projects around the world. As smart city developments surge, the necessity for high-quality steel...

Continue Reading